Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
A new cell therapy is changing the transplant game. Orca-T (Tregzi), the FDA-approved precision-engineered stem cell therapy, showed an 83% 3-year overall survival rate in blood cancer patients — compared to 66% with the standard post-transplant cyclophosphamide approach. The data, drawn from a phase 1b trial and a large registry cohort, suggest Orca-T can meaningfully improve transplant outcomes without sacrificing long-term survival.
A precision cell therapy is proving its staying power. Orca-T (Tregzi), which received FDA approval in June 2026 for use in matched-donor hematopoietic stem cell transplantation (HSCT), is now showing compelling long-term survival data. An observational analysis published in Transplantation and Cellular Therapy compared 76 patients from the phase 1b Orca-T trial against 360 registry patients who received the current standard of care — post-transplant cyclophosphamide (PTCy)-based graft-vs-host disease (GVHD) prophylaxis.
Orca-T works by delivering a carefully engineered mix of donor cells: highly purified regulatory T cells to suppress GVHD, stem and progenitor cells to rebuild the immune system, and conventional T cells to speed immune recovery and fight residual cancer. This precision approach appears to pay off significantly over time.
By the Numbers:
Why it matters: GVHD remains one of the most feared complications of stem cell transplants, and until now, data on how GVHD prevention strategies affect long-term survival have been limited. These findings suggest Orca-T doesn't just reduce GVHD — it may fundamentally improve how long patients live after transplant, making it a potentially practice-changing option for blood cancer care.
